Journal of Clinical Oncology, Vol 7, 1310-1317, Copyright © 1989 by American Society of Clinical Oncology

ARTICLES

Phase II study with the combination etoposide, doxorubicin, and cisplatin in advanced measurable gastric cancer

P Preusser, H Wilke, W Achterrath, U Fink, L Lenaz, A Heinicke, J Meyer, HJ Meyer and H Buente
Department of Surgery, University Clinics, Muenster, West Germany.

In this phase II multicenter trial, 67 evaluable patients with advanced measurable gastric carcinoma were treated with a combination of etoposide, Adriamycin (doxorubicin; Adria Laboratories, Columbus, OH), and cisplatin (EAP). The overall response rate was 64%, including 21% complete responses (CRs). In 55 patients with metastatic disease, 31 responses (51%) including eight CRs (15%) were achieved. Responses were seen in all metastatic sites, but the response rate was lower in patients with peritoneal carcinomatosis. In 12 patients with locoregional disease, six CRs and six partial responses (PRs) were observed. Eight CRs (three and five in patients with metastatic and locoregional disease, respectively) were pathologically confirmed. The overall median response duration was 7 months; it was 16 months for patients achieving CR (22 months for pathologically confirmed CR [pCR]), and 6 months for PR. The median survival time for all patients was 9 months, for the patients who achieved CR 17 months, for pCR 23 months, and for PR 9.5 months. Median survival time for all patients with metastatic disease was 8 months, and for locoregional disease 12.5 months. Six patients (9%) (four local, two metastatic disease) were alive at 2 years, and four patients are alive and disease free at 35+ to 56+ months. Main toxicities were leukopenia and thrombocytopenia, with 64% of patients developing grade 3 to 4 myelosuppression and 12% severe infections. Nonhematologic toxicities of World Health Organization (WHO) grade 4 were not observed.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				Y. TSUTANI, M. OHARA, T. SUZUKI, K. MINAMI, E. MIYAHARA, A. KAMEDA, and Y. NOSO Docetaxel and S-1 as a First-line Treatment in Patients with Advanced or Recurrent Gastric Cancer Anticancer Res, July 1, 2009; 29(7): 2775 - 2779. [Abstract] [Full Text] [PDF]

				G. BAR-SELA, M. TSALIC, M. STEINER, M. WOLLNER, and N. HAIM Local Recurrence following Adjuvant Chemotherapy without Radiotherapy in Completely Resected Stomach and Gastroesophageal Junction Adenocarcinoma Anticancer Res, May 1, 2009; 29(5): 1853 - 1856. [Abstract] [Full Text] [PDF]

				T. Shirasaka Development History and Concept of an Oral Anticancer Agent S-1 (TS-1(R)): Its Clinical Usefulness and Future Vistas Jpn. J. Clin. Oncol., January 1, 2009; 39(1): 2 - 15. [Abstract] [Full Text] [PDF]

				N. Boku, A. Ohtsu, S. Yoshida, K. Shirao, Y. Shimada, I. Hyodo, H. Saito, Y. Miyata, and Gastrointestinal Oncology Study Group of Japan Cli Significance of Biological Markers for Predicting Prognosis and Selecting Chemotherapy Regimens of Advanced Gastric Cancer Patients between Continuous Infusion of 5-FU and a Combination of 5-FU and Cisplatin Jpn. J. Clin. Oncol., May 23, 2007; (2007) hym015v1. [Abstract] [Full Text] [PDF]

				K. Yoshida, M. Ninomiya, N. Takakura, N. Hirabayashi, W. Takiyama, Y. Sato, S. Todo, M. Terashima, M. Gotoh, J. Sakamoto, et al. Phase II Study of Docetaxel and S-1 Combination Therapy for Advanced or Recurrent Gastric Cancer. Clin. Cancer Res., June 1, 2006; 12(11): 3402 - 3407. [Abstract] [Full Text] [PDF]

				F. Nagashima, N. Boku, A. Ohtsu, S. Yoshida, T. Hasebe, A. Ochiai, Y. Sakata, H. Saito, Y. Miyata, I. Hyodo, et al. Biological Markers as a Predictor for Response and Prognosis of Unresectable Gastric Cancer Patients Treated with Irinotecan and Cisplatin Jpn. J. Clin. Oncol., December 1, 2005; 35(12): 714 - 719. [Abstract] [Full Text] [PDF]

				K. Kondo, M. Kobayashi, H. Kojima, N. Hirabayashi, M. Kataoka, K. Araki, T. Matsui, W. Takiyama, Y. Miyashita, H. Nakazato, et al. Phase I Evaluation of Continuous 5-Fluorouracil Infusion Followed by Weekly Paclitaxel in Patients with Advanced or Recurrent Gastric Cancer Jpn. J. Clin. Oncol., June 1, 2005; 35(6): 332 - 337. [Abstract] [Full Text] [PDF]

				S. S. Wohrer, M. Raderer, and M. Hejna Palliative chemotherapy for advanced gastric cancer Ann. Onc., November 1, 2004; 15(11): 1585 - 1595. [Abstract] [Full Text] [PDF]

				A. D. Roth Chemotherapy in gastric cancer: a never ending saga Ann. Onc., February 1, 2003; 14(2): 175 - 177. [Full Text] [PDF]

				K.-D. Lee, T.-W. Liu, C.-W. Wu, C.-M. Tiu, J. M. Liu, T.-R. Chung, J.-Y. Chang, J. Whang-Peng, and L.-T. Chen Non-surgical treatment for afferent loop syndrome in recurrent gastric cancer complicated by peritoneal carcinomatosis: percutaneous transhepatic duodenal drainage followed by 24-hour infusion of high-dose fluorouracil and leucovorin Ann. Onc., July 1, 2002; 13(7): 1151 - 1155. [Abstract] [Full Text] [PDF]

				P. Ross, M. Nicolson, D. Cunningham, J. Valle, M. Seymour, P. Harper, T. Price, H. Anderson, T. Iveson, T. Hickish, et al. Prospective Randomized Trial Comparing Mitomycin, Cisplatin, and Protracted Venous-Infusion Fluorouracil (PVI 5-FU) With Epirubicin, Cisplatin, and PVI 5-FU in Advanced Esophagogastric Cancer J. Clin. Oncol., April 15, 2002; 20(8): 1996 - 2004. [Abstract] [Full Text] [PDF]

				E. Bajetta, R. Buzzoni, L. Mariani, E. Beretta, F. Bozzetti, G. Bordogna, E. Aitini, S. Fava, G. Schieppati, G. Pinotti, et al. Adjuvant chemotherapy in gastric cancer: 5-year results of a randomised study by the Italian Trials in Medical Oncology (ITMO) Group Ann. Onc., February 20, 2002; 13(2): 299 - 307. [Abstract] [Full Text] [PDF]

				N. Boku, A. Ohtsu, F. Nagashima, M. Muto, T. Shinkai, and S. Yoshida Retrospective Study of Hyponatremia in Gastric Cancer Patients Treated with a Combination Chemotherapy of 5-Fluorouracil and Cisplatin: a Possible Warning Sign of Severe Hematological Toxicities? Jpn. J. Clin. Oncol., August 1, 2001; 31(8): 382 - 387. [Abstract] [Full Text] [PDF]

				M. H. Kulke The Treatment of Advanced Gastric Cancer: In Search of the Right Combination J. Clin. Oncol., July 14, 2000; 18(14): 2645 - 2647. [Full Text] [PDF]

				U. Vanhoefer, P. Rougier, H. Wilke, M. P. Ducreux, A. J. Lacave, E. Van Cutsem, M. Planker, J. G. D. Santos, P. Piedbois, B. Paillot, et al. Final Results of a Randomized Phase III Trial of Sequential High-Dose Methotrexate, Fluorouracil, and Doxorubicin Versus Etoposide, Leucovorin, and Fluorouracil Versus Infusional Fluorouracil and Cisplatin in Advanced Gastric Cancer: A Trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cancer Cooperative Group J. Clin. Oncol., July 14, 2000; 18(14): 2648 - 2657. [Abstract] [Full Text] [PDF]

				L. Cirera, A. Balil, E. Batiste-Alentorn, I. Tusquets, T. Cardona, A. Arcusa, L. Jolis, E. Saigi, I. Guasch, A. Badia, et al. Randomized Clinical Trial of Adjuvant Mitomycin Plus Tegafur in Patients With Resected Stage III Gastric Cancer J. Clin. Oncol., December 1, 1999; 17(12): 3810 - 3815. [Abstract] [Full Text] [PDF]

				N. Boku, A. Ohtsu, Y. Shimada, K. Shirao, S. Seki, H. Saito, Y. Sakata, and I. Hyodo Phase II Study of a Combination of Irinotecan and Cisplatin Against Metastatic Gastric Cancer J. Clin. Oncol., January 1, 1999; 17(1): 319 - 319. [Abstract] [Full Text] [PDF]

				I. Songun and C. J.H. van de Velde Can Surgical Treatment Results in Gastric Cancer Be Improved? Oncologist, February 1, 1996; 1(1): 36 - 40. [Abstract] [Full Text] [PDF]

				C. S. Fuchs and R. J. Mayer Gastric Carcinoma N. Engl. J. Med., July 6, 1995; 333(1): 32 - 41. [Full Text] [PDF]

				H. Johnson Jr, C. Belluco, S. Masood, A.-M. Abou-Azama, L. Kahn, and L. Wise The Value of Flow Cytometric Analysis in Patients With Gastric Cancer Arch Surg, March 1, 1993; 128(3): 314 - 317. [Abstract] [PDF]